Drug Trial Radar · NCT05919693
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
33
Actual
Start
Jun 12, 2023
Primary completion
Aug 26, 2024
Study completion Aug 26, 2024
Sponsor
- Lead sponsor
- EyeBiotech Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
EYE103-101 is a 2-part study assessing safety and preliminary efficacy of remigromig (EYE103) in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF. In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of remigromig will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study. In the second part of the study, called the dose finding part two doses of remigromig will be selected and their effectiveness will be compared. Approximately 80 participants will be entered in this part of the study.
Conditions
- Neovascular Age-related Macular Degeneration (NVAMD)
- Diabetic Macular Edema (DME)
Interventions
RemigromigDrug
Remigromig is a humanized antibody formulated for IVT administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)Time frame: Up to approximately 12 weeks
- Number of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 12 weeks
- Number of Participants Who Experienced a Serious Adverse Event (SAE)Time frame: Up to approximately 24 weeks
- Number of Participants Who Experienced Clinically Meaningful Changes in Laboratory AssessmentsTime frame: Baseline and Week 12
- Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) to Week 12 in the Study Eye - DME ParticipantsTime frame: Baseline and Week 12
- Mean Change From Baseline in BCVA to Week 12 in the Study Eye -NVAMD ParticipantsTime frame: Baseline and Week 12
Locations
32 sites in 4 countries. Site status is shown where the registry gives one.
Phoenix, AZ
Phoenix, Arizona
Bakersfield, CA
Bakersfield, California
Modesto, CA
Modesto, California
Mountain View, CA
Mountain View, California
Sacramento, CA
Sacramento, California
Sacramento, CA
Sacramento, California
Colorado Springs, Colorado
Colorado Springs, Colorado
Lakewood, CO
Lakewood, Colorado
Pompano Beach
Pompano Beach, Florida
Lemont, NV
Lemont, Illinois
Hagerstown, MD
Hagerstown, Maryland
Reno, NV
Reno, Nevada
West Columbia, SC
West Columbia, South Carolina
Germantown, TN
Germantown, Tennessee
Knoxville, TN
Knoxville, Tennessee
Nashville, TN
Nashville, Tennessee
Abilene, TX
Abilene, Texas
Amarillo, TX
Amarillo, Texas
Austin, TX
Austin, Texas
Bellaire, TX
Bellaire, Texas
Dallas, TX
Dallas, Texas
Katy, TX
Katy, Texas
McAllen, TX
McAllen, Texas
Plano, TX
Plano, Texas
Round Rock, TX
Round Rock, Texas
San Antonio, TX
San Antonio, Texas
The Woodlands, TX
The Woodlands, Texas
Caba, Argentina
Caba, Argentina
Ciudad Autonoma Buenos Aires
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Arecibo, PR
Arecibo, PR, Puerto Rico
London, UK
London, United Kingdom
London, England
London, England, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.